Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

NCT03367299 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

149

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoid Leukemia
Philadelphia Chromosome-Negative B-Cell Precursor

Interventions

DRUG: Chemotherapy + Blinatumomab

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto